Maxim raised the firm’s price target on Rani Therapeutics (RANI) to $10 from $5 and keeps a Buy rating on the shares after the company announced a licensing deal with Chugai Pharmaceutical for RaniPill technology and a concurrent private placement to raise $60M in proceeds. The Chugai deal offers both non-dilutive financing as well as “key validation” for RaniPill, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RANI: